I Holland's MF80 Automated Punch Polisher
: I Holland’s MF80 Automated Punch Polisher fits seamlessly into the tool room environment ensuring optimum GMP compliance. Increased holder capacity allows more punches to be polished per cycle.
I Holland, the leading specialist manufacturer of tablet tooling for the pharmaceutical and nutraceutical industries has launched the innovative MF80 automated punch polisher, which offers a large capacity for increased polishing per cycle.
MF80 has been designed to increase polishing volume, thanks to the product’s 80 litre drum which can hold up to 17 B or 12 D punches per holder, giving a maximum of 85 B or 60 D punches per polishing cycle.
It offers a solution to overcoming tooling problems like sticking and corrosion, and will polish dull and discoloured punches to a micro fine, high quality finish, by using a drag finishing process. Punches are automatically rotated through media and polishing paste, saving time over manual polishing operations and ensuring a consistent result.
The importance of maintaining tools is essential to extending the life of tablet tooling and by using a machine like the MF80 as part of the I Holland 7 Step PharmaCare®process, a professional maintenance and storage programme, tooling life will be extended.
The new automated punch polisher offers a smooth operation, whilst improving efficiency in the tablet press resulting in a quality tablet. Operated via touchscreen software and available in several languages, the MF80 is now used by manufacturers’ world-wide.
Contact Details:
I Holland
Website:www.iholland.co.ukE-mail: info@iholland.co.uk
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
